224 related articles for article (PubMed ID: 28888997)
1. Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells.
Bashari O; Redko B; Cohen A; Luboshits G; Gellerman G; Firer MA
Cancer Lett; 2017 Nov; 408():164-173. PubMed ID: 28888997
[TBL] [Abstract][Full Text] [Related]
2. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells.
Kalimuthu K; Lubin BC; Bazylevich A; Gellerman G; Shpilberg O; Luboshits G; Firer MA
J Nanobiotechnology; 2018 Mar; 16(1):34. PubMed ID: 29602308
[TBL] [Abstract][Full Text] [Related]
3. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
4. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
[TBL] [Abstract][Full Text] [Related]
5. Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents.
Newton-Northup JR; Figueroa SD; Deutscher SL
Comb Chem High Throughput Screen; 2011 Jan; 14(1):9-21. PubMed ID: 20958260
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
7. Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer.
Wang W; Chen X; Li T; Li Y; Wang R; He D; Luo W; Li X; Wu X
Exp Cell Res; 2013 May; 319(8):1156-64. PubMed ID: 23466786
[TBL] [Abstract][Full Text] [Related]
8. Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion.
Romanov VI; Durand DB; Petrenko VA
Prostate; 2001 Jun; 47(4):239-51. PubMed ID: 11398171
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display.
Northup JR; Deutscher SL
Comb Chem High Throughput Screen; 2016; 19(5):370-7. PubMed ID: 27055748
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance to chlorambucil in murine B-cell leukemic cells is overcome by its conjugation to a targeting peptide.
Gellerman G; Baskin S; Galia L; Gilad Y; Firer MA
Anticancer Drugs; 2013 Feb; 24(2):112-9. PubMed ID: 23187462
[TBL] [Abstract][Full Text] [Related]
11. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).
Sotomayor S; Muñoz-Moreno L; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Cancer; 2010 Oct; 127(8):1813-22. PubMed ID: 20099275
[TBL] [Abstract][Full Text] [Related]
12. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
[TBL] [Abstract][Full Text] [Related]
13. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
14. Metastatic prostate cancer cell-specific phage-like particles as a targeted gene-delivery system.
Fagbohun OA; Kazmierczak RA; Petrenko VA; Eisenstark A
J Nanobiotechnology; 2013 Sep; 11():31. PubMed ID: 24059645
[TBL] [Abstract][Full Text] [Related]
15. G3-C12 Peptide Reverses Galectin-3 from Foe to Friend for Active Targeting Cancer Treatment.
Sun W; Li L; Yang Q; Shan W; Zhang Z; Huang Y
Mol Pharm; 2015 Nov; 12(11):4124-36. PubMed ID: 26393405
[TBL] [Abstract][Full Text] [Related]
16. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
17. Identification of a LNCaP-specific binding peptide using phage display.
Qin B; Tai W; Shukla RS; Cheng K
Pharm Res; 2011 Oct; 28(10):2422-34. PubMed ID: 21611873
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Targeting Peptides Search Strategy for the Delivery of Therapeutic and Diagnostic Molecules to Tumor Cells.
Dmitrieva MD; Voitova AA; Dymova MA; Richter VA; Kuligina EV
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396774
[TBL] [Abstract][Full Text] [Related]
19. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
[TBL] [Abstract][Full Text] [Related]
20. Targeted nanomedicine modalities for prostate cancer treatment.
Cohen L; Livney YD; Assaraf YG
Drug Resist Updat; 2021 May; 56():100762. PubMed ID: 33857756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
